Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10.56 SEK | +5.81% | -0.19% | +213.35% |
05-07 | Transcript : Ascelia Pharma AB - Special Call | |
05-02 | Ascelia Pharma AB Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+213.35% | 32.69M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- ACE Stock
- News Ascelia Pharma AB
- Transcript : Ascelia Pharma AB - Special Call